RE:Delta 9 2nd Quarterly ReportJust a few things I notice when looking at financials. The 7 million you note for Q2-2020 gross profit includes 2.5 million in biological asset adjustments. I don't think this can be relied upon to add to gross margin going forward. Would be nice if each quarter can just be breakeven on the biological asset adjusmtents.
I think the success of Q2-2021 depends on how the B2B segment bounces back. Looking back to Q2-2020, that quarter included nearly 3 million in B2B sales, which is a high margin segment. However, Q1-2021 had less than $200,000 in B2B sales. At 3/31/21, though, the Grow Pods for Resale inventory was sitting at 2 million. If they can move these pods and show solid quarter in their B2B sales, that should lead to a nice quarter in top line sales, as well as some sequential improvement in gross profitability.
The last several quarters have seen growth in retail, relatively constant wholesale numbers, and decreasing B2B. If they can get all 3 segments to provide solid results in the same quarter, that's when we see movement in the stock price. Maybe that will be Q2-2021, or at least I can hope.